Aibili Logo Association for Innovation and Biomedical Research on Light

Latest Ongoing Projects

Coimbra Coordinating Centre for Clinical Research

Characterization of potential biomarkers of Eye Disease and Vision Loss (EyeMarker). [more info]

Apoio na análise de dados e na elaboração de trabalhos científicos para estudos observacionais/retrospetivos da AIBILI/CHUC. (STAT) [more info]

Five-year incidence of Age-related Macular Degeneration in the central region of Portugal (AMDIncidence_CPT) [more info]

Centre for Clinical Trials

E3 Consortium to promote and sustain collaboration and sharing of data and knowledge in the field of ophthalmic epidemiology in Europe. E3 [more info]

A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis (Protocol CTFY720D2399) [more info]

Randomized, open label multi-center study comparing cabazitaxel at 25 mg/m2 in combination with prednisone every 3 weeks to Docexatel in combination with prednisone in patients with metastatic castration resistant prostate cancer not pre-treated with chemotherapy (Firstana) (Protocol EFC11784) [more info]

Centre of New Technologies for Medicine

Area of retinal layers disruption calculation tool [more info]

C-Tracer OCT Automatic Segmentation [more info]

FILTER – Framework to Develop and Validate Automated Image Analysis Systems for Early Diagnosis and Treatment of Eyes at Risk in Blinding Age-Related Disease [more info]

Coimbra Ophthalmology Reading Centre

A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 when administered alone or in combination with Lucentis®, in diabetic macular oedema (DME) patients with a poor or no response to anti vascular endothelial growth factor (anti-VEGF) treatment. (Protocol THR-317-002) [more info]

A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa. (Protocol GS030_CLIN_001) [more info]

RetmarkerAMD Software Validation [more info]

Centre for Health Technology Assessment and Drug Research

Budget impact analysis of Kalydeco [more info]

Evaluation of the therapeutic value of Alecensa [more info]

Evaluation of the therapeutic value of Parsabiv [more info]

Pharmacovigilance Unit of Coimbra

Unidade de farmacovigilância de coimbra [more info]

Data Centre

eCRF Design and Development, IT support and Training and Long Term Data Storage Services for GS030 Study [more info]

eCRF Design and Development, IT support and Training and Long Term Data Storage Services for MADEOS Study [more info]

Ongoing IT Support, Data Storage and Long Term Data Storage Services for PROGRESS Study [more info]

Projects by department:

Copyright © AIBILI   -   Contact Us   -   Site Map   -   Webdesign Glitz Design   -   Programming Bizview